Centre Hospitalier De Pau
- Address
- lock Available on a paid plan
Cardiovascular Research
The clinical trial portfolio at Centre Hospitalier De Pau includes important work in cardiovascular diseases, especially atrial fibrillation and acute coronary syndrome. These studies are focused on improving the prevention of serious heart- and stroke-related events and on comparing new treatment options with current standard care.
- Preventing stroke and other embolic complications in atrial fibrillation
- Reducing major cardiovascular events after heart attack or related acute coronary syndrome
- Evaluating whether new therapies can improve protection beyond existing treatment approaches
This area reflects a strong interest in safer and more effective long-term management of cardiovascular disease.
Digestive System Disease Studies
Research in digestive system diseases is a major focus at this hospital, with trials addressing ulcerative colitis and bowel urgency. The goal is to better control symptoms, improve remission rates, and support patients living with chronic inflammatory bowel conditions.
- Improving symptom control in moderately to severely active ulcerative colitis
- Testing new treatments aimed at achieving clinical remission and endoscopic improvement
- Assessing whether therapies can reduce bowel urgency and improve daily quality of life
These studies highlight ongoing efforts in gastroenterology to refine treatment options for persistent digestive inflammation.
Oncology and Cancer Care
The oncology trials at Centre Hospitalier De Pau cover several neoplasms, including melanoma, small bowel adenocarcinoma, colon carcinoma, advanced non-small cell lung cancer, and cutaneous squamous cell carcinoma. These studies are designed to evaluate new cancer treatments, improve disease control, and extend the time patients remain free from progression or recurrence.
- Testing treatment strategies for melanoma and high-risk resected disease
- Exploring new options for small bowel adenocarcinoma, colon cancer, and lung cancer
- Assessing therapies for advanced cutaneous squamous cell carcinoma that is difficult to treat with surgery or radiotherapy
Overall, this research aims to improve outcomes in both early and advanced cancer settings through better treatment selection and disease control.
Digestive Physiology and Treatment Response
Another part of the site’s research activity focuses on digestive system and oral physiological phenomena, with studies designed to understand how patients respond to therapy and how symptoms change over time. This work supports more personalized care in gastroenterology by linking symptom relief with treatment effectiveness.
- Monitoring changes in digestive symptoms during treatment for ulcerative colitis
- Evaluating how well therapies improve patient-reported digestive comfort and function
- Supporting research that connects symptom improvement with broader disease control
These investigations complement the site’s broader focus on chronic digestive disease management and patient-centered outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 16 therapeutic areas and 15 of 196 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 188 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier De Pau
lock Showing 1 of 94 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 196 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 16 | Unknown | 2018-08-24 | 2025-12-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.